Wednesday, November 29, 2017
Cannabics Pharmaceuticals Inc. (CNBX) announced today that it has received a new research license from the Israeli Ministry of Health for the Characterization of anti-tumor activity of cannabinoids.
The new license will enable the company to continue our vision of developing an ecosystem for creation of diagnostic tools and bringing to the market diagnostic services for cancer patients who are medicated with cannabis. Our forward looking plan encompasses a synergy between HTS (High Throughput Screening), CTCs (Circulating Tumor Cells), Drug Efficacy, and Genomic Data to provide therapists and their patients with personalized supportive data for their treatment.
